Fred Eshelman is the founder and CEO of Eshelman Ventures, a private investment company in Wilmington, North Carolina. See contact routes.
Fred Eshelman is the founder and CEO of Eshelman Ventures, a private investment company in Wilmington, North Carolina, that primarily targets healthcare firms. He previously founded Pharmaceutical Product Development (PPD), serving as its CEO and Executive Chairman before its sale to private equity. His investment thesis centers on life sciences, biotechnology, and pharmaceutical sectors, focusing on innovative ventures advancing medical treatments and patient care. Eshelman typically serves on the boards of portfolio companies, indicating a lead investor role with active governance involvement. Notable portfolio companies include Aravive, which received a $10.0 million investment from his firm in 2022, and Eyenovia Inc., where he filed an activist investment disclosure in 2023. He also chairs Furiex Pharmaceuticals and has backed Breakthru Medicine, a Series A biotech startup. While no public writing is cited, his consistent support for life sciences innovation and strategic guidance through board participation defines his distinctive investor profile.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Wilmington when building a target list.
Investors like Fred Eshelman · Full investor directory · Investor access · Company funding database